





LETTER FROM THE FOUNDER

Saberg Clinical Research was founded in 2014 in The Netherlands. Our organization was initially established as a trusted partner for a group of small-to-medium clients based in the United States, who were seeking to efficiently and skilfully conduct their clinical development programs. Throughout the years and as we grew, we remained true to our initial mission.

Our work is based on several pillars: highest level of competence, enthusiasm as the main motivator, availability around the clock, outmost dedication to our clients, transparent and simply-constructed costs and loyalty.

Supporting our clients achieve their milestones within the pressure of venture capital and stock exchange finance environments we understand that “by EOB today” really means “by the end of the business day today”.

Our work ethic, the atmosphere we create and the exceptional results we have had so far, have proudly led us to a virtually zero-turnover of both clients as well as among our team members alike.

Looking forward to working with you!

Dr Sandrin Bergheanu, MD, PhD

ABOUT SABERG CLINICAL RESEARCH


We are an internationally operating clinical research group with a focus on medical monitoring.

We cover all stages of clinical drug development: from first-in-human phase I to phase IV post-marketing clinical trials as well as expanded access/compassionate use programs.


Besides the extensive scientific knowledge and experience with all facets of medical monitoring, our team is routined in the global process of drug development. Therefore, the medical monitoring activities that we perform are seamlessly embedded with pharmacovigilance, medical writing, clinical operations, regulatory and finance.

We pride ourselves on building strong relationships with our clients and becoming agile extensions of their team. The Saberg Group consists of MDs / MD, PhDs and clinical scientists with relevant backgrounds for each project, and proven track records.

We believe that having the right specialists, the experience, and the dedication combined with the open, rapid and efficient communication, irrespective of location and time zone difference are the key factors to achieving success.



OUR SERVICES



OUR SERVICES

FOCUS ON MEDICAL MONITORING

Medical monitoring is at the core of our activities, either as stand-alone services or acting as Medical Directors for clients that do not have medical teams in-house. We provide the full range of activities, they include the following:

- Review and advise on the subjects' eligibility for the clinical programs based on protocol inclusion / exclusion criteria.
- Evaluation of medical history, concomitant medications, vital signs, physical examinations, lab results, ECGs, imaging, specific tests, etc.
- Periodic reviews of the emerging data and round-the-clock medical monitoring.
- Supervision of pharmacovigilance processes for the recording and reporting of all types of adverse events.
- Evaluation and review of adverse events, serious adverse events and SUSARs.
- Medical review of all relevant program-related forms and documents.
- Protocol training of the study teams for the medical procedures and evaluations.
- Serve as a liaison between the clients and the research site's medical staff.
- Supervision of the Data and Safety Monitoring Board (DSMB) and Clinical Endpoint Committee (CEC) activities.
- Support the interactions with the National Competent Authorities and Institutional Review Boards/Ethics Committees.

IN ADDITION TO MEDICAL MONITORING...



SITE SELECTION

We provide assistance with site selection - because we understand the specifics of each individual development program, we help our clients select the appropriate investigational sites.

A MODERN APPROACH

We take a modern approach to clinical research - we help our clients select suitable research partners, design and perform innovative trials.



ABOUT SANDRIN BERGHEANU

OUR LEADERSHIP TEAM

Sandrin Bergheanu, MD, PhD is a physician - clinical pharmacologist with more than 15 years of experience in drug development.

Sandrin graduated from the Carol Davila Medical School in Bucharest, Romania. He then worked at the University Hospital of Geneva (HUG), Switzerland before moving to the Leiden University Medical Center (LUMC) in Leiden, the Netherlands. While at LUMC, he obtained his PhD in Cardiovascular Research through a combined program at the Department of Cardiology and the Department of Clinical Epidemiology.

Sandrin was trained as a clinical pharmacologist at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands and LUMC. He has also received extensive training in clinical study design and biostatistics. He has participated in the design and execution of clinical trials (phase I, phase II, and large phase III trials) for the pharmaceutical industry, medical device companies, and academic consortia. Sandrin has extensive experience with US-based clients.

Prior to founding Saberg Clinical Research, Sandrin was the Medical Director at Sticares (a Netherlands-based CRO that specializes in cardiovascular research) and Medical Advisor at Eli Lilly and Company. Sandrin speaks English, Dutch, French, Italian and Romanian.

[Publication List](#)



CONTACT US

The Netherlands (HQ)
Parkstraat 83, 2514 JG
The Hague

P: +31 (0) 703 538 154
F: +31 (0) 703 538 333
office@saberg.org

www.saberg.org